The value of serum bcl-2 levels in advanced epithelial ovarian cancer

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 213-217

  Tas, Faruk ^a   Duranyildiz, Derya ^a   Oguz, Hilal ^a   Camlica, Hakan ^a   Yasasever, Vildan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Bcl 2; Ovarian cancer, advanced; Serum

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PACLITAXEL; PROTEIN BCL 2; SERUM ALBUMIN; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; CA-125 ANTIGEN; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 33646879400     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:213     Document Type: Article

References (27)

1. Jong D, et al. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 1994; 54: 256-260.
2. Martin B. et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003; 89: 55-64.
3. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumors. Br J Cancer 1995; 72(5): 1324-1329.
4. Witty JP, Jensen RA, Johnson AL. Expression and localization of Bcl-2 related proteins in human ovarian cancers. Anticancer Res 1998; 18(2B): 1223-1230.
5. Wehrli BM, et al. Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors. Int J Gynaecol Pathol 1998; 17(3): 255-260.
6. Marone M, et al. Bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998; 4(2): 517-524.
7. Zusman I, Gurevich P, Gurevich E, Ben-Hur H. The immune system, apoptosis and apoptosis-related proteins in human ovarian tumors (a review). Int J Oncol 2001; 18(5): 965-972.
8. Fauvet R, et al. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours. Virchoes Arch 2002; 443(1): 38-43.
9. Sagarra RA, et al. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer 2002; 12(6): 720-727.
10. Diebold J, et al. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996; 105(3): 341-349.
11. Skirnisdottir I, Seidal T, Gerdin E, Sorbe B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 2002; 12(3): 265-276.
12. Skirnisdottir I, Sorbe B, Seidal T. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11(2): 147-158.
13. Kassim SK, et al. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem 1999; 32(5):333-338.
14. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 2001; 19(3): 537-542.
15. Preethi TR, et al. Apoptosis in epithelial ovarian tumors. Pathol Res Pract 2002; 198(4): 273-280.
16. Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R. Clinical significance of apoptosis-related factors p53, mdm2, and bcl-2 in advanced ovarian cancer. J Clin Oncol 1999; 17(7): 2061-2068.
17. Okuma Y, et al. Correlation between expression of oncogene products and resistance to anticaner drugs in cultured ovarian cancer cell lines. Hum Cell 2003; 16(3): 131-139.
18. Protopapas A, et al. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian caner patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol 2004; 25(2): 225-229.
19. Yang X, et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 2004; 130(7): 423-428.
20. Herod JJ, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56(9): 2178-2184.
21. Kupryjanczyk J, et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 2003; 88(6): 848-854.
22. Schuyer M, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 2001; 85(9): 1359-1367.
23. Baekelandt M, Holm R, Nesland JM, Trope CG, Kristensen GB. Expression of apoptosis-related proteins is an independent determinants of patient prognosis in advanced ovarian cancer. J Clin Oncol 2000; 18(22): 3775-3781.
24. Marx D, et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997; 17(3C): 2233-2240.
25. Geisler JP, et al. P53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000; 77(2): 278-282.
26. Berker B, Dunder I, Ensari A, Cengiz SD, Simsek E. Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol 2002; 23(6): 505-510.
27. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 2003; 16(6): 574-583.